10.20.14
Miamisburg, Ohio-based X-Spine Systems Inc. has added a line of biologics to its product portfolio. The initial launch of biologics includes Axograft DBM (demineralized bone matrix) putty, Axograft cancellous crushed allograft, Axograft crunch allograft and Axograft amniotic membrane.
The Axograft biological line will complement X-Spine’s existing line of spinal fixation products. They will be used to promote spinal fusion, bone healing and wound treatment in spinal arthrodesis procedures.
“We are excited to expand our spinal treatment portfolio with the addition of the X-Spine Axograft line of biologics. This launch exemplifies our continuing strategy to extend the X-Spine footprint beyond our fixation products, and incorporate a broader view of the treatment of spine disease into biological and interventional arenas,” said X-Spine CEO, Dr. David Kirschman, M.D.
Over the past 10 months, X-Spine has launched five different spine surgical systems and devices. In the pipeline is the Irix-A lumbar integrated fusion system, which was recently cleared by the U.S. Food and Drug Administration and will be launched in the fourth quarter of 2014.
The Axograft biological line will complement X-Spine’s existing line of spinal fixation products. They will be used to promote spinal fusion, bone healing and wound treatment in spinal arthrodesis procedures.
“We are excited to expand our spinal treatment portfolio with the addition of the X-Spine Axograft line of biologics. This launch exemplifies our continuing strategy to extend the X-Spine footprint beyond our fixation products, and incorporate a broader view of the treatment of spine disease into biological and interventional arenas,” said X-Spine CEO, Dr. David Kirschman, M.D.
Over the past 10 months, X-Spine has launched five different spine surgical systems and devices. In the pipeline is the Irix-A lumbar integrated fusion system, which was recently cleared by the U.S. Food and Drug Administration and will be launched in the fourth quarter of 2014.